Skip to main content

Table 1 Univariate analysis of predictors of early hepatic flare.

From: Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand

 

EHF

(n = 8)

Non-EHF

(n = 28)

p-value

Age yrs (median, IQR)

37 (33-42)

33 (28-40)

0.25

Male gender

88%

43%

0.12

HBeAg positive

50%

64%

0.47

Alcohol (> 3units/day)

25%

25%

1.00

Cirrhosis

20%

42%

0.36

HBV Genotype C

75%

82%

0.28

BMI kg/m2 (median. IQR)

19 (18-20)

20 (18-22)

0.20

BL CD4 cells/mm3 (median. IQR)

52 (18-131)

32 (19-214)

0.96

BL HIV RNA log10 c/ml (median. IQR)

4.9 (4.7-5.1)

4.7 (4.3-5.1)

0.22

BL ALT IU/L (median. IQR)

79 (59-96)

36 (22-59)

0.008*

BL HBV DNA log10 c/ml (median. IQR)

9.9 (8.4-10.4)

8.4 (7.8-9.0)

0.009*

Randomised HBV therapy

3TC n = 5

3TC n = 8

0.193

 

TDF n = 2

TDF n = 10

 
 

3TC/TDF n = 1

3TC/TDF n = 10

 

OI prophylaxis

(fluconazole and/or cotrimoxazole)

88%

61%

0.162

Izoniazid therapy

0%

21%

0.302

  1. All comparisons made using the Mann-Whitney U-test except categorical variables where Chi-squared or Fischers Exact test used
  2. *Statistically significant at p < 0.05